H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Viracta Therapeutics to $4 from $10 and keeps a Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VIRX:
- Viracta Therapeutics Provides Clinical Update and Outlook for 2024
- Viracta Therapeutics announces ODD granted by U.S. FDA to nana-val
- Viracta Therapeutics granted orphan status for carcinoma treatment
- Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
- Viracta Therapeutics announces interim data from Phase 1b/2 trial of nana-val